2QG Stock Chart & Stats
€0.07
€0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range€0.07 - €0.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€5.01M
Enterprise Value€7.34M
Total Cash (Recent Filing)€301.02K
Total Debt (Recent Filing)€2.64M
Price to Earnings (P/E)―
Beta-0.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding69,709,950
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-2.05
Price to Sales (P/S)502592.05
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
2QG FAQ
What was Quantum Genomics Societe Anonyme’s price range in the past 12 months?
Quantum Genomics Societe Anonyme lowest stock price was €0.07 and its highest was €0.07 in the past 12 months.
What is Quantum Genomics Societe Anonyme’s market cap?
Quantum Genomics Societe Anonyme’s market cap is €5.01M.
When is Quantum Genomics Societe Anonyme’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Quantum Genomics Societe Anonyme’s earnings last quarter?
Currently, no data Available
Is Quantum Genomics Societe Anonyme overvalued?
According to Wall Street analysts Quantum Genomics Societe Anonyme’s price is currently Undervalued.
Does Quantum Genomics Societe Anonyme pay dividends?
Quantum Genomics Societe Anonyme does not currently pay dividends.
What is Quantum Genomics Societe Anonyme’s EPS estimate?
Quantum Genomics Societe Anonyme’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Quantum Genomics Societe Anonyme have?
Quantum Genomics Societe Anonyme has 69,709,950 shares outstanding.
What happened to Quantum Genomics Societe Anonyme’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Quantum Genomics Societe Anonyme?
Currently, no hedge funds are holding shares in DE:2QG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quantum Genomics Societe Anonyme
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.